RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Gilead Sciences (NASDAQ:GILD) but lowered the price target from $76 to $75.
February 14, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Gilead Sciences but reduced the price target from $76 to $75.
The adjustment in price target by RBC Capital, while maintaining the same rating, suggests a slight adjustment in valuation expectations without a fundamental change in the company's outlook. This could lead to short-term price stability or minor fluctuations as the market digests this new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100